In the life sciences industry, electrification is often framed as a carbon reduction tactic. It makes sense. By changing processes, systems or pieces of equipment that burn fossil fuels to ones that consume electricity, organizations will see an inevitable impact on their environmental footprint.

But that’s just one part of the story. Our latest research with Verdantix shows that its value runs far deeper. Electrification not only allows for faster progress towards net zero commitments, but it also directly supports pharma’s top strategic priorities: strengthening resilience and business continuity (number one), reducing operating costs and improving efficiency (a close second) and reinforcing the industry’s non‑negotiable standards of compliance and regulatory adherence .

With oil prices and supply looking less predictable, this is becoming a priority topic in almost every conversation I’m having across the industry. Although that doesn’t mean it’s going to be easy; companies are also facing significant barriers to advancing electrification projects.

Here, I'm going to explore how electrifying processes, systems and equipment translate into strategic benefits for life sciences companies and how they can effectively move ahead.

Why does electrification translate into energy and operational resilience?

First, let’s look at this purely from a power supply perspective. Electrified systems reduce exposure to volatile fuel markets and make it easier to integrate renewables and backup power. The result is greater protection against price and supply shocks. And because these systems connect more seamlessly to uninterrupted power supply (UPS), battery storage and microgrids, they also support resilient GMP performance, creating a more predictable, controllable energy environment for critical operations ‒ all while advancing decarbonization.

Beyond energy supply, the resilience benefits become even more pronounced. Electrified systems are easier to connect, monitor and automate – and once equipment is electrically powered and controlled, adding sensors and capturing data becomes far simpler. That means issues are identified earlier, reducing downtime from both power disruptions and equipment failure.

According to our survey with Verdantix, 96% of respondents rate downtime reduction as critical ‒ it’s their top resilience priority. Electrified equipment can be monitored continuously, so maintenance needs can be predicted with far greater accuracy before they interrupt GMP operations.

How electrification improves compliance while cutting operational costs

The benefits of this level of control support the industry’s other top priorities. When electrified systems are integrated with IoT sensors, compliance becomes automated rather than retrospective. Instead of relying on manual checks, systems can automatically verify temperature, humidity and pressure conditions ‒ that are essential for keeping lab and manufacturing environments within spec. These records are stored automatically, so at audit time, everything is already in place.

There’s also the energy cost dimension. Once equipment runs on electricity ‒ and is connected to a digital energy management system ‒ teams gain granular control over how and when energy is used, consuming only what they need rather than burning fuel continuously.

Right now, most pharma teams aren’t fully realizing these benefits ‒ which only come when digital systems are integrated into a central, unified platform. According to our interviews, only 23% of companies have reached a high level of integration, which allows for real time optimization . Most have only moderately integrated systems.

One challenge is that digital connectivity also increases the digital footprint that could be targeted. The industry is only too aware of this, with 82% of respondents rating cybersecurity as critical to electrification projects . As life sciences facilities become more connected and regulations become more demanding, Information Technology (IT) and Operational Technology (OT) environments must both be protected, with cybersecurity baked into digitalized infrastructure from day one.

If they can achieve secure digital integration, organizations can expect lower energy bills, fewer disruptions to GMP operations and a more stable, predictable cost base.

Many still face significant barriers to moving forward with electrification projects. Upfront investment remains the biggest blocker, and downtime is the top operational concern. Shutting down facilities for upgrades is in direct conflict with one of the main issues that electrification is meant to solve.

Modular deployment strategies and pay‑as‑you‑go financing models can help ease both the financial and operational burden, and these approaches are increasingly viable.

For example, we developed a comprehensive energy supply solution for Ferring’s new site in Kiel, a facility dedicated to the production, freeze-drying and microencapsulation of pharmaceuticals. Beyond providing state-of-the-art digital measurement and control technologies to reduce energy consumption and enable proactive maintenance, Siemens has taken over the technical management of the energy center for 12 years, with a full-service contract guaranteeing energy efficiency and availability.

Shifting spending from CapEx to OpEx means costs are more predictable, reducing financial risk and making it easier for companies to justify investments internally and align with budget cycles.

When organizations stop treating electrification as a standalone hardware upgrade and look at it from a broader perspective ‒ not just as a change in how equipment is powered, but as an enabler of data‑driven decision‑making ‒ the business case becomes far stronger. And that is where the real strategic benefits lie: strengthening resilience, improving business continuity, reducing operating costs and driving greater efficiency across facilities.

Find the full report here